Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy-naive patients with unresectable or metastatic pancreatic cancer

Tigatuzumab is the humanized version of the agonistic murine monoclonal antibody TRA-8 that binds to the death receptor 5 and induces apoptosis of human cancer cell lines via the caspase cascade. The combination of tigatuzumab and gemcitabine inhibits tumor growth in murine pancreatic xenografts. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Forero-Torres, Andres, Infante, Jeffrey R, Waterhouse, David, Wong, Lucas, Vickers, Selwyn, Arrowsmith, Edward, He, Aiwu Ruth, Hart, Lowell, Trent, David, Wade, James, Jin, Xiaoping, Wang, Qiang, Austin, TaShara, Rosen, Michael, Beckman, Robert, von Roemeling, Reinhard, Greenberg, Jonathan, Saleh, Mansoor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2013
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3892397/
https://www.ncbi.nlm.nih.gov/pubmed/24403266
http://dx.doi.org/10.1002/cam4.137

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3892397/
https://www.ncbi.nlm.nih.gov/pubmed/24403266
http://dx.doi.org/10.1002/cam4.137

Ejemplares similares